Then, successive studies have shown that ARID1A mutations are also present in other cancers, such as 29% in gastric cancer, 10-17% in hepatocellular carcinoma, 10% in colorectal cancer, and 13% in bladder cancer (23, 27–31). This evidence concerns the gene ARID1A and hepatocellular carcinoma.